Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

479
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
479
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

615
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
615
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

544
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
544
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

375
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
375
What is Monogastric Digestion?01:50

What is Monogastric Digestion?

74.8K
The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
74.8K
Cancer Therapies02:49

Cancer Therapies

9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Small molecule activators of the mitochondrial protease ClpP induce senescence in triple-negative breast cancer cells and sensitize cells to the Bcl-2 inhibitor venetoclax.

Cell death & disease·2026
Same author

Fatty Acid Oxidation Suppression Reprograms Fibroblasts in Fibrostenotic Crohn's Disease.

bioRxiv : the preprint server for biology·2026
Same author

Commercially Purchased and In-House Bred C57BL/6 Mice with Different Gut Microbiota Exhibit Distinct Indomethacin-Induced Toxicities.

Gut microbes reports·2026
Same author

Sex-dependent responses in mice to indomethacin-induced organ injury and gut microbiome-targeted alleviation.

Scientific reports·2025
Same author

Commercially Purchased and In-House Bred C57BL/6 Mice with Different Gut Microbiota Exhibit Distinct Indomethacin-Induced Toxicities.

bioRxiv : the preprint server for biology·2025
Same author

Photothrombolytics: A light-driven technology for the targeted lysis of thrombi.

Journal of controlled release : official journal of the Controlled Release Society·2024

Related Experiment Video

Updated: Dec 29, 2025

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.3K

Relationship Between the Gut Microbiome and Systemic Chemotherapy.

Samantha M Ervin1, Siddharth Venkat Ramanan2, Aadra P Bhatt3

  • 1Department of Chemistry, University of North Carolina at Chapel Hill, 250 Bell Tower Drive, Chapel Hill, NC, 27599, USA.

Digestive Diseases and Sciences
|February 7, 2020
PubMed
Summary

The gut microbiome influences chemotherapy effectiveness and side effects. Targeting gut bacteria may reduce toxicity and improve cancer treatment outcomes for patients.

Keywords:
ChemotherapyGastrointestinal toxicityMicrobiome

More Related Videos

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing
11:22

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing

Published on: October 15, 2019

30.9K
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.6K

Related Experiment Videos

Last Updated: Dec 29, 2025

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.3K
Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing
11:22

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing

Published on: October 15, 2019

30.9K
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.6K

Area of Science:

  • Microbiology
  • Pharmacology
  • Oncology

Background:

  • The intestinal microbiome possesses significant metabolic capabilities, influencing drug metabolism.
  • Bacterial enzymes in the gut can alter the activity and bioavailability of pharmaceutical compounds, including chemotherapeutics.
  • Gastrointestinal toxicity is a major challenge in systemic chemotherapy, leading to adverse events like nausea, vomiting, and diarrhea.

Purpose of the Study:

  • To explore the impact of the intestinal microbiome on chemotherapeutic metabolism and toxicity.
  • To investigate how microbiota-mediated drug alterations affect patient prognosis and treatment efficacy.
  • To highlight the potential of targeting the gut microbiota for personalized cancer medicine.

Main Methods:

  • Multidisciplinary approaches to study the mechanistic interactions between bacterial enzymes and drugs.
  • Analysis of how microbiota composition and function influence drug bioactivity and bioavailability.
  • Investigation of direct and indirect mechanisms by which gut bacteria alter drug activity.

Main Results:

  • Microbiota significantly impact the metabolism of various drugs, including chemotherapeutics.
  • Alterations in drug activity by gut bacteria can lead to severe gastrointestinal side effects.
  • These toxicities necessitate treatment adjustments, potentially compromising patient prognosis.

Conclusions:

  • Targeting the gut microbiota offers a promising strategy to mitigate chemotherapy-induced toxicities.
  • Understanding the microbiome's role can lead to improved prognostic biomarkers and prediction of treatment response.
  • Personalized medicine approaches incorporating microbiome analysis can enhance cancer patient care and outcomes.